{"gene":"TM6SF2","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":2014,"finding":"TM6SF2 is required for normal VLDL secretion; AAV-mediated shRNA knockdown of Tm6sf2 in mice increased liver triglyceride content ~3-fold and decreased VLDL secretion by ~50%. The E167K variant produces ~50% less protein than wild-type when expressed in cultured hepatocytes, indicating the variant causes loss of function.","method":"AAV-shRNA knockdown in mice (in vivo), recombinant protein expression in cultured hepatocytes","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — clean in vivo KO with defined metabolic phenotype, replicated across multiple independent populations and validated in cell culture","pmids":["24531328"],"is_preprint":false},{"year":2014,"finding":"TM6SF2 localizes to the endoplasmic reticulum and ER-Golgi intermediate compartment (ERGIC) of human liver cells. siRNA inhibition reduces secretion of triglyceride-rich lipoproteins (TRLs) and increases cellular triglyceride/lipid droplet content, while overexpression reduces hepatocyte steatosis.","method":"Confocal microscopy for subcellular localization; siRNA knockdown and overexpression in Huh7 and HepG2 cells with lipoprotein secretion assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — direct localization experiment with functional consequence, complementary KD and OE with defined phenotypic readouts","pmids":["24927523"],"is_preprint":false},{"year":2014,"finding":"Transient TM6SF2 overexpression or Tm6sf2 knockdown in mice alters serum lipid profiles consistent with human association data, confirming TM6SF2 as the functional gene at the 19p13 locus influencing total cholesterol.","method":"In vivo mouse overexpression and knockdown experiments with serum lipid profiling","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — in vivo gain- and loss-of-function experiments with quantitative lipid phenotyping","pmids":["24633158"],"is_preprint":false},{"year":2016,"finding":"Genetic inactivation of Tm6sf2 in mice causes hepatic steatosis, hypocholesterolemia, and transaminitis. TM6SF2 protein localizes to the ER and Golgi complex. VLDL-TG secretion is reduced ~3-fold without reduction in apoB secretion, indicating TM6SF2 is required to mobilize neutral lipids for VLDL lipidation but not for apoB-containing lipoprotein particle secretion per se. Excess lipids accumulate in lipid droplets.","method":"Germline Tm6sf2 knockout mouse; immunocytochemistry; cell fractionation; VLDL-TG secretion rate measurement; apoB secretion assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — germline KO with multiple orthogonal mechanistic readouts including fractionation, secretion rates, and lipid quantification","pmids":["27013658"],"is_preprint":false},{"year":2017,"finding":"Hepatic Tm6sf2 overexpression in mice reduces plasma lipid levels and hepatic TG secretion and increases hepatosteatosis, recapitulating the KO phenotype. In cultured human hepatocytes, Tm6sf2 overexpression reduces apolipoprotein B secretion and causes APOB accumulation within the ER, suggesting impaired ER-to-Golgi trafficking of pre-VLDL particles. Both E167K and L156P coding variants affect TM6SF2 protein stability (altered protein turnover).","method":"AAV-mediated hepatic overexpression in mice; APOB trafficking assay in cultured hepatocytes; protein turnover analysis of coding variants","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — in vivo overexpression with lipid phenotyping plus mechanistic cell culture experiments with defined trafficking readout","pmids":["28449094"],"is_preprint":false},{"year":2020,"finding":"TM6SF2 forms a complex with ERLIN1, ERLIN2, and APOB (identified by tandem affinity purification/mass spectrometry). ERLINs and TM6SF2 mutually stabilize each other. TM6SF2 binds and stabilizes APOB via two luminal loops. ERLINs stabilize APOB indirectly through TM6SF2. The E167K mutation reduces TM6SF2 protein expression and thereby destabilizes APOB. Knockout of Tm6sf2 or Erlins in mice decreases hepatic APOB protein, causing hepatic lipid accumulation and lower serum lipids.","method":"Tandem affinity purification + mass spectrometry; Co-IP; mutagenesis of TM6SF2 luminal loops; Tm6sf2 and Erlin knockdown/KO in mice","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1–2 — AP-MS identification of interacting proteins followed by reciprocal Co-IP, domain mutagenesis, and in vivo validation","pmids":["32776921"],"is_preprint":false},{"year":2021,"finding":"Liver-specific Tm6sf2 knockout (Tm6sf2 LKO) mice develop spontaneous hepatic steatosis with VLDL-TG secretion reduced and small, underlipidated VLDL particles produced with unchanged or increased apoB. Feeding fibrogenic diets exacerbates steatosis and fibrosis, and promotes HCC. AAV8-mediated rescue with either wild-type or E167K-mutant Tm6sf2 reduces hepatic steatosis and restores VLDL secretion, and attenuates tumor burden.","method":"Liver-specific conditional KO mice; targeted lipidomics; VLDL-TG secretion assay; AAV8 rescue; HCC models (NASH/STAM and DEN injection)","journal":"Hepatology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 2 — two independent LKO lines, rescue experiment, multiple dietary/carcinogen HCC models with quantitative endpoints","pmids":["33638902"],"is_preprint":false},{"year":2021,"finding":"TM6SF2 is present predominantly in the smooth ER and ERGIC (not Golgi) of hepatocytes and enterocytes, determined by cell fractionation. TM6SF2 acts in the smooth ER to promote bulk lipidation of apoB-containing lipoproteins. By immunoprecipitation, both apolipoprotein B-48 and acyl-CoA synthetase long chain family member 5 (ACSL5) physically interact with TM6SF2.","method":"Cell fractionation; immunoprecipitation; Tm6sf2-/- rat model; perfused liver VLDL lipid content assay; mass spectrometry identification of interacting proteins","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"High","confidence_rationale":"Tier 1–2 — subcellular fractionation with functional validation, reciprocal Co-IP identifying specific interacting proteins, independent rat KO model","pmids":["34923175"],"is_preprint":false},{"year":2017,"finding":"TM6SF2 knockdown in HuH7 hepatoma cells alters membrane lipid composition: accumulation of TAGs, cholesterol esters, PC, and PE, with selective depletion of polyunsaturated lipid species (especially arachidonic acid) and increase in saturated/monounsaturated species. Mitochondrial capacity for palmitate oxidation is significantly reduced. Secreted lipoprotein-like particles are smaller in KD cells.","method":"Stable siRNA knockdown in HuH7 cells; lipidomic analysis; mitochondrial fatty acid oxidation assay; lipoprotein particle sizing","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"Medium","confidence_rationale":"Tier 2 — single lab with multiple orthogonal lipid and functional assays in stable KD cells","pmids":["28434889"],"is_preprint":false},{"year":2017,"finding":"TM6SF2 E167K carrier hepatocytes show impaired incorporation of polyunsaturated fatty acids (PUFAs) into triglycerides and phosphatidylcholines (PCs). Liver biopsies from E167K carriers have higher TG and CE but lower PC levels, with PUFA deficiency in liver and serum TGs and liver PCs. TM6SF2 knockdown in HuH-7 cells recapitulates reduced PUFA incorporation into TGs and PCs.","method":"Liver biopsies with lipidomic analysis; TM6SF2 knockdown in HuH-7 cells with fatty acid incorporation assay; gene expression analysis","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 2 — human liver biopsy lipidomics combined with mechanistic cell culture validation; two orthogonal approaches","pmids":["28235613"],"is_preprint":false},{"year":2018,"finding":"TM6SF2 promotes lipidation and secretion of hepatitis C virus lipoviroparticles (LVPs). TM6SF2 knockdown in hepatocytes reduces HCV RNA and infectious LVP secretion without affecting HCV replication, translation, or assembly. TM6SF2 overexpression increases LVP secretion into culture supernatant in lower-density fractions. HCV infection upregulates TM6SF2 expression via SREBF2.","method":"TM6SF2 knockdown and overexpression in hepatic cells; iodixanol gradient assay for LVP density; HCV infection assay; measurement of viral RNA and infectious titers; humanized mouse and patient biopsy analysis","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal KD/OE with specific functional readouts, validated in humanized mouse and human biopsies","pmids":["30144428"],"is_preprint":false},{"year":2021,"finding":"TM6SF2 CRISPR/Cas9 silencing in HepG2 cells alters lipid composition, induces accumulation of microvesicular lipid droplets, disrupts ER and mitochondrial ultrastructure, increases ER/oxidative stress, and increases mitochondrial number (reflecting imbalanced mitochondrial dynamics). Double knockout of MBOAT7 and TM6SF2 impairs mitochondrial activity with a shift toward anaerobic glycolysis and increases cell proliferation rate. Re-overexpression of TM6SF2 reverses these metabolic and tumorigenic features.","method":"CRISPR/Cas9 knockout in HepG2 cells; electron microscopy of ER/mitochondria ultrastructure; lipidomics; metabolic flux analysis; rescue by re-expression","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"High","confidence_rationale":"Tier 2 — CRISPR KO with multiple orthogonal mechanistic readouts and rescue experiment","pmids":["34823063"],"is_preprint":false},{"year":2021,"finding":"TM6SF2 interacts with inositol-requiring enzyme 1α (IRE1α), a primary ER stress sensor. Male E167K knock-in mice exhibit impaired glucose tolerance and impaired IRE1α signaling in the liver, while female KI mice are unaffected, linking TM6SF2 to ER stress regulation in a sex-specific manner.","method":"E167K knock-in mouse model; glucose tolerance tests; Co-IP of TM6SF2 with IRE1α; hepatic IRE1α signaling assays","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 — KI mouse model with defined phenotype plus Co-IP identifying IRE1α interaction; single lab","pmids":["34746691"],"is_preprint":false},{"year":2022,"finding":"Myeloid-specific Tm6sf2 knockout (on ApoE-/- background) inhibits atherosclerosis and reduces foam cell formation without changing plasma lipid profiles. TM6SF2 silencing in macrophages reduces inflammatory responses, ER stress, cholesterol uptake, and foam cell formation; overexpression has opposite effects. TM6SF2 is upregulated by oxidized LDL in macrophages.","method":"Myeloid-specific Tm6sf2 KO mice (LysM-Cre); Western diet atherosclerosis model; RNA-seq of BMDMs; THP-1 macrophage siRNA/OE experiments; cholesterol uptake and foam cell assays","journal":"Cells","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific in vivo KO with defined atherosclerosis phenotype plus mechanistic cell culture validation","pmids":["36139452"],"is_preprint":false},{"year":2023,"finding":"TM6SF2 reduces lipid accumulation in vascular smooth muscle cells (VSMCs) by downregulating LOX-1 (lectin-like oxLDL receptor 1) and CD36 (scavenger receptor) expression in response to oxLDL stimulation.","method":"siRNA knockdown and overexpression of TM6SF2 in human aortic VSMCs; lipid accumulation assay; LOX-1 and CD36 expression analysis","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, single cell type, no in vivo validation","pmids":["37271250"],"is_preprint":false},{"year":2024,"finding":"The TM6SF2 E167K variant increases the interaction between TM6SF2 and PNPLA3, and impairs PNPLA3-mediated transfer of polyunsaturated fatty acids (PUFAs) from triglycerides to phosphatidylcholines (PCs). E167K KI mice on HFD show decreased polyunsaturated PC and increased polyunsaturated TG. Dietary supplementation with PC containing C18:3 attenuates E167K-induced hepatic steatosis in HFD mice.","method":"Tm6sf2 E167K knock-in mice; hepatic lipidomics; thin-layer chromatography of newly synthesized TG/PC; Co-IP of TM6SF2 with PNPLA3; dietary rescue experiment","journal":"Clinical and molecular hepatology","confidence":"High","confidence_rationale":"Tier 2 — KI mouse model plus Co-IP plus lipidomics plus dietary rescue; multiple orthogonal methods","pmids":["39054606"],"is_preprint":false},{"year":2024,"finding":"TM6SF2 directly binds IKKβ and inhibits NF-κB signaling, thereby reducing IL-6 secretion from hepatocytes. This mechanism activates cytotoxic CD8+ T cells and suppresses MASLD-related HCC. Hepatocyte-specific Tm6sf2 KO increases IL-6 and reduces IFN-γ+CD8+ T cells in tumors; IL-6 neutralization abolishes the tumor-promoting effect of Tm6sf2 KO.","method":"Hepatocyte-specific Tm6sf2 KO mice; HFHC diet and DEN-induced HCC models; orthotopic HCC model; Co-IP of TM6SF2 with IKKβ; IL-6 neutralization; CD8+ T cell depletion; adenovirus-mediated rescue","journal":"Gut","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific KO with mechanistic Co-IP, rescue, and depletion experiments across multiple HCC models","pmids":["39667906"],"is_preprint":false},{"year":2025,"finding":"Intestinal epithelial cell-specific Tm6sf2 knockout (Tm6sf2ΔIEC) mice develop MASH accompanied by impaired intestinal barrier and microbial dysbiosis. Stool transplant from Tm6sf2ΔIEC mice induces steatohepatitis in germ-free recipients. Mechanistically, Tm6sf2-deficient intestinal cells interact with fatty acid-binding protein 5 (FABP5) to secrete more free fatty acids, causing gut barrier dysfunction and enrichment of pathobionts. This elevates lysophosphatidic acid (LPA) that translocates to the liver to promote lipid accumulation and inflammation.","method":"Intestinal-specific Tm6sf2 KO mice; germ-free fecal transplant; co-housing rescue; Co-IP with FABP5; LPA receptor pharmacological inhibition; gut microbiome analysis","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic models (IEC-KO, GF transplant, co-housing), mechanistic Co-IP, and pharmacological intervention with defined pathway","pmids":["39779889"],"is_preprint":false},{"year":2024,"finding":"In iPSC-derived hepatocytes carrying the TM6SF2 E167K mutation, TM6SF2 protein expression is decreased, intracellular lipid droplets and total cholesterol are increased, and VLDL secretion is reduced. Signs of ER stress and mitochondrial dysfunction are observed. Facilitating protein folding within the ER of E167K hepatocytes improves VLDL secretion and reduces ER stress markers.","method":"CRISPR gene editing of iPSCs; hepatocyte-directed differentiation; lipidomics; transcriptomics; ER chaperone treatment rescue experiment","journal":"Hepatology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 — human iPSC-derived hepatocyte model with mechanistic rescue experiment; single lab","pmids":["40833996"],"is_preprint":false},{"year":2024,"finding":"Inhibition (knockdown) of TM6SF2 in viral hepatitis cell culture models suppresses secretion of infectious HCV virions, HDV virions, and HBV subviral particles, indicating TM6SF2 functions in the ER-Golgi secretion pathway exploited by multiple hepatitis viruses.","method":"TM6SF2 knockdown in HBV, HCV, HDV cell culture infection models; measurement of secreted infectious particles and subviral particles; correlation with human cohort polymorphism data","journal":"The Journal of infectious diseases","confidence":"Medium","confidence_rationale":"Tier 2 — consistent KD phenotype across three different viral infection models; human cohort validation","pmids":["38408366"],"is_preprint":false},{"year":2014,"finding":"Computational sequence analysis identified a conserved EXPERA domain shared among TM6SF2, MAC30/TMEM97, and EBP (D8/D7 sterol isomerase) protein families, predicting that TM6SF2 may possess catalytic activity as a sterol isomerase.","method":"Computational protein sequence analysis and evolutionary conservation analysis","journal":"Frontiers in genetics","confidence":"Low","confidence_rationale":"Tier 4 — computational prediction only, no experimental validation","pmids":["25566323"],"is_preprint":false}],"current_model":"TM6SF2 is an ER-resident polytopic membrane protein (also present in the ERGIC) that promotes bulk lipidation of nascent apoB-containing VLDL particles in the smooth ER by physically interacting with APOB, ACSL5, ERLIN1/2, and PNPLA3; loss of function (including the E167K variant, which destabilizes the protein) impairs PUFA incorporation into phosphatidylcholines and reduces VLDL-TG secretion, causing hepatic lipid droplet accumulation, while in macrophages TM6SF2 promotes cholesterol uptake and inflammation, and in intestinal cells it regulates free fatty acid secretion via FABP5 to modulate the gut-liver LPA axis; additionally, hepatic TM6SF2 suppresses NF-κB/IL-6 signaling by binding IKKβ to maintain anti-tumor CD8+ T cell immunity, and facilitates ER-Golgi secretion of hepatitis B, C, and D viruses."},"narrative":{"teleology":[{"year":2014,"claim":"Establishing TM6SF2 as the causal gene at the 19p13 NAFLD/dyslipidemia locus resolved a key gene-assignment question: in vivo knockdown caused hepatic steatosis and reduced VLDL secretion, while E167K reduced protein levels, defining loss-of-function as the disease mechanism.","evidence":"AAV-shRNA knockdown in mice; recombinant expression of WT vs E167K in hepatocytes; independent overexpression/knockdown mouse cohorts with serum lipid profiling","pmids":["24531328","24633158"],"confidence":"High","gaps":["No structural data for TM6SF2 or the E167K mutation","Mechanism by which TM6SF2 promotes lipidation unknown","Tissue-specific contributions not resolved"]},{"year":2014,"claim":"Subcellular localization to the ER and ERGIC placed TM6SF2 at the site of VLDL assembly and linked its function to the early secretory pathway rather than post-Golgi trafficking.","evidence":"Confocal microscopy and cell fractionation in Huh7/HepG2 cells; siRNA/overexpression with lipoprotein secretion readouts","pmids":["24927523"],"confidence":"High","gaps":["Whether TM6SF2 cycles between ER and ERGIC or is static was unresolved","Identity of direct protein partners unknown"]},{"year":2016,"claim":"Germline Tm6sf2 KO demonstrated that TM6SF2 is specifically required for neutral-lipid loading onto VLDL (reduced VLDL-TG without reduced apoB secretion), separating bulk lipidation from particle assembly.","evidence":"Germline Tm6sf2 knockout mouse with VLDL-TG secretion rates and apoB secretion measurement","pmids":["27013658"],"confidence":"High","gaps":["How TM6SF2 mobilizes neutral lipids to VLDL remained unknown","Lipid species specificity not yet characterized"]},{"year":2017,"claim":"Lipidomic analyses of TM6SF2-deficient cells and E167K carrier livers revealed selective impairment of polyunsaturated fatty acid incorporation into triglycerides and phosphatidylcholines, identifying a lipid-species-specific function beyond bulk TG mobilization.","evidence":"Lipidomics of human liver biopsies from E167K carriers; fatty acid incorporation assays in TM6SF2-knockdown HuH-7 cells; membrane lipid profiling of stable KD cells","pmids":["28235613","28434889"],"confidence":"High","gaps":["Enzymatic versus scaffolding role in PUFA channeling unclear","No direct enzymatic assay performed"]},{"year":2017,"claim":"Overexpression studies showed that excess TM6SF2 impairs ER-to-Golgi trafficking of APOB, and that both E167K and L156P reduce protein stability, indicating that TM6SF2 dosage — not just presence — is critical for VLDL export.","evidence":"AAV-mediated hepatic overexpression in mice; APOB trafficking in cultured hepatocytes; protein turnover of coding variants","pmids":["28449094"],"confidence":"High","gaps":["Whether overexpression artifact or true stoichiometric requirement was debated","Degradation pathway of destabilized TM6SF2 not identified"]},{"year":2018,"claim":"Discovery that TM6SF2 promotes HCV lipoviroparticle secretion without affecting viral replication or assembly extended TM6SF2 function from endogenous lipoprotein export to virus egress, exploiting the same ER lipidation machinery.","evidence":"TM6SF2 knockdown/overexpression in HCV-infected hepatocytes; iodixanol gradient density profiling of secreted virions; humanized mouse validation","pmids":["30144428"],"confidence":"High","gaps":["Whether TM6SF2 directly contacts viral proteins or acts only via lipoprotein lipidation was unclear","Applicability to other hepatitis viruses not tested"]},{"year":2020,"claim":"Identification of a TM6SF2–ERLIN1/2–APOB complex revealed the molecular partners through which TM6SF2 stabilizes APOB in the ER: two luminal loops of TM6SF2 bind APOB directly, while ERLINs stabilize the complex, explaining how E167K reduces APOB protein.","evidence":"Tandem affinity purification–mass spectrometry; reciprocal Co-IP; luminal loop mutagenesis; Tm6sf2 and Erlin KO mice","pmids":["32776921"],"confidence":"High","gaps":["Stoichiometry of the complex undefined","Whether ERLIN-TM6SF2 interaction is constitutive or regulated unknown","No structural model of the complex"]},{"year":2021,"claim":"Liver-specific Tm6sf2 KO confirmed cell-autonomous hepatocyte function and showed that TM6SF2 loss promotes diet-dependent fibrosis and HCC, with rescue by AAV-delivered WT or E167K TM6SF2, establishing TM6SF2 as a liver tumor suppressor.","evidence":"Liver-specific conditional KO mice; NASH/STAM and DEN HCC models; AAV8 rescue with WT and E167K","pmids":["33638902"],"confidence":"High","gaps":["HCC mechanism (steatosis-driven vs direct signaling) not dissected","Whether E167K rescue reflects residual function or dosage restoration unclear"]},{"year":2021,"claim":"Refined fractionation placed TM6SF2 in the smooth ER and ERGIC (not Golgi), and identification of ACSL5 as a physical partner linked TM6SF2 to fatty acyl-CoA metabolism at the site of VLDL lipidation.","evidence":"Cell fractionation of hepatocytes and enterocytes; immunoprecipitation identifying apoB-48 and ACSL5 as partners; Tm6sf2 KO rat model","pmids":["34923175"],"confidence":"High","gaps":["Functional consequence of ACSL5 interaction not tested by ACSL5 perturbation","Whether TM6SF2 channels acyl-CoAs directly to VLDL or lipid droplets unknown"]},{"year":2021,"claim":"CRISPR knockout revealed that TM6SF2 loss disrupts ER and mitochondrial ultrastructure, increases ER/oxidative stress, shifts metabolism toward glycolysis, and promotes cell proliferation — linking TM6SF2 to organelle homeostasis and tumorigenesis beyond lipid secretion.","evidence":"CRISPR/Cas9 KO in HepG2; electron microscopy; metabolic flux analysis; rescue by re-expression; MBOAT7/TM6SF2 double KO","pmids":["34823063"],"confidence":"High","gaps":["Whether mitochondrial phenotype is secondary to ER lipid overload or a direct TM6SF2 function unresolved","In vivo replication of metabolic reprogramming not performed"]},{"year":2022,"claim":"Myeloid-specific Tm6sf2 KO demonstrated a non-hepatocyte role: TM6SF2 promotes macrophage cholesterol uptake and inflammation, and its deletion reduces atherosclerosis, revealing cell-type-dependent opposing effects on disease.","evidence":"LysM-Cre myeloid-specific Tm6sf2 KO on ApoE⁻/⁻ background; Western diet atherosclerosis model; THP-1 siRNA/OE with cholesterol uptake assays","pmids":["36139452"],"confidence":"High","gaps":["Molecular mechanism of cholesterol uptake promotion in macrophages not identified","Whether hepatic and macrophage functions share the same molecular partners unknown"]},{"year":2024,"claim":"Co-IP showed that E167K increases TM6SF2 interaction with PNPLA3, impairing PNPLA3-mediated PUFA transfer from TG to PC; dietary PC supplementation rescued steatosis, establishing the TM6SF2–PNPLA3 axis as a targetable lipid-remodeling pathway.","evidence":"E167K knock-in mice on HFD; Co-IP of TM6SF2 with PNPLA3; TLC of newly synthesized TG/PC; dietary rescue with C18:3-containing PC","pmids":["39054606"],"confidence":"High","gaps":["Whether TM6SF2 directly modulates PNPLA3 catalytic activity or only proximity unknown","Structural basis of increased E167K–PNPLA3 interaction not determined"]},{"year":2024,"claim":"Identification of IKKβ as a TM6SF2 binding partner and demonstration that TM6SF2 suppresses NF-κB/IL-6 signaling to maintain CD8⁺ T cell anti-tumor immunity revealed a non-lipid, immunomodulatory mechanism through which TM6SF2 loss promotes HCC.","evidence":"Hepatocyte-specific Tm6sf2 KO; HFHC and DEN HCC models; Co-IP with IKKβ; IL-6 neutralization; CD8⁺ T cell depletion; adenovirus rescue","pmids":["39667906"],"confidence":"High","gaps":["Whether IKKβ binding is direct or mediated by a complex member unclear","Relationship between lipid and NF-κB functions not disentangled"]},{"year":2024,"claim":"Extending the viral egress function, TM6SF2 knockdown suppressed secretion of HBV subviral particles and HDV virions alongside HCV, establishing TM6SF2 as a shared host factor for multiple hepatitis viruses.","evidence":"TM6SF2 knockdown in HBV, HCV, and HDV cell culture infection models; secreted particle quantification","pmids":["38408366"],"confidence":"Medium","gaps":["No in vivo viral model tested","Whether TM6SF2 acts via a common lipidation step for all viruses or through distinct mechanisms unresolved"]},{"year":2025,"claim":"Intestinal epithelial-specific Tm6sf2 KO and germ-free fecal transplant demonstrated that TM6SF2 in enterocytes maintains gut-barrier integrity; loss increases FABP5-dependent free fatty acid secretion, microbial dysbiosis, and LPA-mediated liver injury, establishing a gut-liver axis for TM6SF2-driven MASH.","evidence":"IEC-specific Tm6sf2 KO mice; germ-free fecal microbiota transplant; Co-IP with FABP5; LPA receptor inhibition; microbiome analysis","pmids":["39779889"],"confidence":"High","gaps":["Whether intestinal TM6SF2–FABP5 interaction governs the same PUFA-channeling seen in hepatocytes unknown","Contribution of intestinal vs hepatic TM6SF2 loss to human MASH not quantified"]},{"year":null,"claim":"No high-resolution structure of TM6SF2 exists, the catalytic versus scaffolding nature of TM6SF2 in lipid remodeling is unresolved, and how its lipid-trafficking and NF-κB-suppressive functions are coordinated remains an open question.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure available","Whether TM6SF2 possesses enzymatic (e.g. sterol isomerase) activity remains untested experimentally","Integration of hepatocyte, macrophage, and enterocyte functions into a unified model lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[8,9,15]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,16]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[5,7]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1,3,7]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[7]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,3,6,8,9,15]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[4,5,7,10]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[12,16]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13,16]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[6,10,11,19]}],"complexes":["TM6SF2–ERLIN1/2–APOB complex"],"partners":["APOB","ERLIN1","ERLIN2","ACSL5","PNPLA3","FABP5","IKBKB","ERN1"],"other_free_text":[]},"mechanistic_narrative":"TM6SF2 is an ER-resident polytopic membrane protein that controls the lipidation and secretion of apolipoprotein B-containing lipoproteins, with broad roles in hepatic, intestinal, and macrophage lipid metabolism, innate immune signaling, and hepatitis virus egress. In the smooth ER and ERGIC, TM6SF2 physically interacts with APOB, ACSL5, ERLIN1/2, and PNPLA3 to promote bulk neutral-lipid loading of nascent VLDL particles and the channeling of polyunsaturated fatty acids from triglycerides into phosphatidylcholines; loss of function — including the common E167K destabilizing variant — reduces VLDL-TG secretion and causes hepatic steatosis, ER stress, and progression to fibrosis and hepatocellular carcinoma [PMID:24531328, PMID:27013658, PMID:32776921, PMID:39054606]. Beyond lipoprotein metabolism, TM6SF2 suppresses NF-κB/IL-6 signaling by binding IKKβ to sustain anti-tumor CD8⁺ T cell immunity in the liver, promotes cholesterol uptake and inflammatory responses in macrophages, and in intestinal epithelial cells interacts with FABP5 to regulate free fatty acid secretion and gut-barrier integrity via the lysophosphatidic acid–liver axis [PMID:39667906, PMID:36139452, PMID:39779889]. TM6SF2 also facilitates ER-to-Golgi secretion of hepatitis B, C, and D virions, linking its lipid-trafficking function to the life cycles of multiple hepatotropic viruses [PMID:30144428, PMID:38408366]."},"prefetch_data":{"uniprot":{"accession":"Q9BZW4","full_name":"Transmembrane 6 superfamily member 2","aliases":[],"length_aa":377,"mass_kda":42.6,"function":"Regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content (PubMed:24531328, PubMed:24927523). May function as sterol isomerase (PubMed:25566323)","subcellular_location":"Endoplasmic reticulum membrane; Endoplasmic reticulum-Golgi intermediate compartment membrane","url":"https://www.uniprot.org/uniprotkb/Q9BZW4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TM6SF2","classification":"Not Classified","n_dependent_lines":17,"n_total_lines":1208,"dependency_fraction":0.014072847682119206},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TM6SF2","total_profiled":1310},"omim":[{"mim_id":"606563","title":"TRANSMEMBRANE 6 SUPERFAMILY, MEMBER 2; TM6SF2","url":"https://www.omim.org/entry/606563"},{"mim_id":"606562","title":"TRANSMEMBRANE 6 SUPERFAMILY, MEMBER 1; TM6SF1","url":"https://www.omim.org/entry/606562"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":71.1},{"tissue":"liver","ntpm":32.0}],"url":"https://www.proteinatlas.org/search/TM6SF2"},"hgnc":{"alias_symbol":["Lpr4"],"prev_symbol":[]},"alphafold":{"accession":"Q9BZW4","domains":[{"cath_id":"-","chopping":"9-192","consensus_level":"high","plddt":92.3398,"start":9,"end":192},{"cath_id":"-","chopping":"202-362","consensus_level":"high","plddt":95.7191,"start":202,"end":362}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BZW4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BZW4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BZW4-F1-predicted_aligned_error_v6.png","plddt_mean":91.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TM6SF2","jax_strain_url":"https://www.jax.org/strain/search?query=TM6SF2"},"sequence":{"accession":"Q9BZW4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BZW4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BZW4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BZW4"}},"corpus_meta":[{"pmid":"24531328","id":"PMC_24531328","title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24531328","citation_count":962,"is_preprint":false},{"pmid":"24978903","id":"PMC_24978903","title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24978903","citation_count":485,"is_preprint":false},{"pmid":"24927523","id":"PMC_24927523","title":"TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24927523","citation_count":284,"is_preprint":false},{"pmid":"24633158","id":"PMC_24633158","title":"Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24633158","citation_count":236,"is_preprint":false},{"pmid":"32190914","id":"PMC_32190914","title":"Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.","date":"2020","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/32190914","citation_count":187,"is_preprint":false},{"pmid":"27013658","id":"PMC_27013658","title":"Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27013658","citation_count":173,"is_preprint":false},{"pmid":"26457389","id":"PMC_26457389","title":"Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study.","date":"2015","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26457389","citation_count":110,"is_preprint":false},{"pmid":"28235613","id":"PMC_28235613","title":"Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.","date":"2017","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/28235613","citation_count":106,"is_preprint":false},{"pmid":"34532996","id":"PMC_34532996","title":"TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease.","date":"2021","source":"Hepatology communications","url":"https://pubmed.ncbi.nlm.nih.gov/34532996","citation_count":101,"is_preprint":false},{"pmid":"25457209","id":"PMC_25457209","title":"Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.","date":"2014","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/25457209","citation_count":96,"is_preprint":false},{"pmid":"26822232","id":"PMC_26822232","title":"Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.","date":"2016","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26822232","citation_count":89,"is_preprint":false},{"pmid":"31406127","id":"PMC_31406127","title":"The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31406127","citation_count":89,"is_preprint":false},{"pmid":"34823063","id":"PMC_34823063","title":"TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models.","date":"2021","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/34823063","citation_count":88,"is_preprint":false},{"pmid":"26272871","id":"PMC_26272871","title":"Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.","date":"2015","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/26272871","citation_count":87,"is_preprint":false},{"pmid":"33638902","id":"PMC_33638902","title":"Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.","date":"2021","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/33638902","citation_count":85,"is_preprint":false},{"pmid":"25893821","id":"PMC_25893821","title":"TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children.","date":"2015","source":"Pediatric obesity","url":"https://pubmed.ncbi.nlm.nih.gov/25893821","citation_count":69,"is_preprint":false},{"pmid":"34923175","id":"PMC_34923175","title":"Hepatic TM6SF2 Is Required for Lipidation of VLDL in a Pre-Golgi Compartment in Mice and Rats.","date":"2021","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/34923175","citation_count":66,"is_preprint":false},{"pmid":"25566323","id":"PMC_25566323","title":"TM6SF2 and MAC30, new enzyme homologs in sterol metabolism and common metabolic disease.","date":"2014","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25566323","citation_count":51,"is_preprint":false},{"pmid":"32776921","id":"PMC_32776921","title":"Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease.","date":"2020","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32776921","citation_count":48,"is_preprint":false},{"pmid":"25581573","id":"PMC_25581573","title":"TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.","date":"2015","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/25581573","citation_count":46,"is_preprint":false},{"pmid":"28449094","id":"PMC_28449094","title":"Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28449094","citation_count":45,"is_preprint":false},{"pmid":"31752753","id":"PMC_31752753","title":"Association of TM6SF2 rs58542926 T/C gene polymorphism with hepatocellular carcinoma: a meta-analysis.","date":"2019","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31752753","citation_count":42,"is_preprint":false},{"pmid":"28242789","id":"PMC_28242789","title":"TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD.","date":"2017","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/28242789","citation_count":42,"is_preprint":false},{"pmid":"30875804","id":"PMC_30875804","title":"TM6SF2 and MBOAT7 Gene Variants in Liver Fibrosis and Cirrhosis.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30875804","citation_count":33,"is_preprint":false},{"pmid":"30824369","id":"PMC_30824369","title":"Meta-analysis of the association between MBOAT7 rs641738, TM6SF2 rs58542926 and nonalcoholic fatty liver disease susceptibility.","date":"2019","source":"Clinics and research in hepatology and gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/30824369","citation_count":29,"is_preprint":false},{"pmid":"28434889","id":"PMC_28434889","title":"Depletion of TM6SF2 disturbs membrane lipid composition and dynamics in HuH7 hepatoma cells.","date":"2017","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/28434889","citation_count":27,"is_preprint":false},{"pmid":"29232562","id":"PMC_29232562","title":"TM6SF2: A novel target for plasma lipid regulation.","date":"2017","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/29232562","citation_count":27,"is_preprint":false},{"pmid":"29574608","id":"PMC_29574608","title":"Fish intake interacts with TM6SF2 gene variant to affect NAFLD risk: results of a case-control study.","date":"2018","source":"European journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/29574608","citation_count":27,"is_preprint":false},{"pmid":"32093693","id":"PMC_32093693","title":"Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.","date":"2020","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/32093693","citation_count":22,"is_preprint":false},{"pmid":"27278285","id":"PMC_27278285","title":"Meta-analysis of the influence of TM6SF2 E167K variant on Plasma Concentration of Aminotransferases across different Populations and Diverse Liver Phenotypes.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27278285","citation_count":20,"is_preprint":false},{"pmid":"34692725","id":"PMC_34692725","title":"PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial.","date":"2021","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34692725","citation_count":20,"is_preprint":false},{"pmid":"31054977","id":"PMC_31054977","title":"Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.","date":"2019","source":"Annals of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/31054977","citation_count":19,"is_preprint":false},{"pmid":"30727943","id":"PMC_30727943","title":"Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population.","date":"2019","source":"BMC biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30727943","citation_count":19,"is_preprint":false},{"pmid":"30271746","id":"PMC_30271746","title":"The Genetics of Clinical Liver Diseases: Insight into the TM6SF2 E167K Variant.","date":"2018","source":"Journal of clinical and translational hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/30271746","citation_count":16,"is_preprint":false},{"pmid":"39054606","id":"PMC_39054606","title":"TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD.","date":"2024","source":"Clinical and molecular hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/39054606","citation_count":16,"is_preprint":false},{"pmid":"34746691","id":"PMC_34746691","title":"Type 2 diabetes sex-specific effects associated with E167K coding variant in TM6SF2.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/34746691","citation_count":15,"is_preprint":false},{"pmid":"32568739","id":"PMC_32568739","title":"Association of the NCAN-TM6SF2-CILP2-PBX4-SUGP1-MAU2 SNPs and gene-gene and gene-environment interactions with serum lipid levels.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32568739","citation_count":15,"is_preprint":false},{"pmid":"34590679","id":"PMC_34590679","title":"Meta-GWAS of PCSK9 levels detects two novel loci at APOB and TM6SF2.","date":"2022","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34590679","citation_count":14,"is_preprint":false},{"pmid":"29761171","id":"PMC_29761171","title":"Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.","date":"2018","source":"Hepatology communications","url":"https://pubmed.ncbi.nlm.nih.gov/29761171","citation_count":14,"is_preprint":false},{"pmid":"34503201","id":"PMC_34503201","title":"Lipid Droplet-Associated Factors, PNPLA3, TM6SF2, and HSD17B Proteins in Hepatopancreatobiliary Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34503201","citation_count":13,"is_preprint":false},{"pmid":"39779889","id":"PMC_39779889","title":"Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis.","date":"2025","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/39779889","citation_count":13,"is_preprint":false},{"pmid":"30144428","id":"PMC_30144428","title":"TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes.","date":"2018","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/30144428","citation_count":13,"is_preprint":false},{"pmid":"35978872","id":"PMC_35978872","title":"Mechanism and therapeutic strategy of hepatic TM6SF2-deficient non-alcoholic fatty liver diseases via in vivo and in vitro experiments.","date":"2022","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/35978872","citation_count":13,"is_preprint":false},{"pmid":"35057689","id":"PMC_35057689","title":"Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease.","date":"2022","source":"Expert review of gastroenterology & hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35057689","citation_count":12,"is_preprint":false},{"pmid":"29088779","id":"PMC_29088779","title":"The additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on lipid metabolism.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29088779","citation_count":12,"is_preprint":false},{"pmid":"38465912","id":"PMC_38465912","title":"Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism.","date":"2024","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/38465912","citation_count":11,"is_preprint":false},{"pmid":"26756786","id":"PMC_26756786","title":"Associations of TM6SF2 167K allele with liver enzymes and lipid profile in children: the PANIC Study.","date":"2016","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/26756786","citation_count":11,"is_preprint":false},{"pmid":"39667906","id":"PMC_39667906","title":"Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy.","date":"2025","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/39667906","citation_count":10,"is_preprint":false},{"pmid":"28950858","id":"PMC_28950858","title":"Identification of deleterious rare variants in MTTP, PNPLA3, and TM6SF2 in Japanese males and association studies with NAFLD.","date":"2017","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/28950858","citation_count":10,"is_preprint":false},{"pmid":"36139452","id":"PMC_36139452","title":"Myeloid TM6SF2 Deficiency Inhibits Atherosclerosis.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36139452","citation_count":9,"is_preprint":false},{"pmid":"28407767","id":"PMC_28407767","title":"E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6.","date":"2017","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/28407767","citation_count":9,"is_preprint":false},{"pmid":"27784963","id":"PMC_27784963","title":"TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.","date":"2016","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/27784963","citation_count":9,"is_preprint":false},{"pmid":"33565643","id":"PMC_33565643","title":"Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis.","date":"2021","source":"Alimentary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33565643","citation_count":8,"is_preprint":false},{"pmid":"30161167","id":"PMC_30161167","title":"PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30161167","citation_count":8,"is_preprint":false},{"pmid":"34575933","id":"PMC_34575933","title":"Perturbation of TM6SF2 Expression Alters Lipid Metabolism in a Human Liver Cell Line.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34575933","citation_count":6,"is_preprint":false},{"pmid":"30944816","id":"PMC_30944816","title":"TM6SF2 E167K Variant Overexpression Promotes Expression of Inflammatory Cytokines in the HCC Cell Line HEPA 1-6.","date":"2019","source":"Journal of clinical and translational hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/30944816","citation_count":6,"is_preprint":false},{"pmid":"38776916","id":"PMC_38776916","title":"The common p.Ile291Val variant of ERLIN1 enhances TM6SF2 function and is associated with protection against MASLD.","date":"2024","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38776916","citation_count":6,"is_preprint":false},{"pmid":"30616151","id":"PMC_30616151","title":"Relationship between N,N-dimethylformamide exposure, PNPLA3, GCKR, COL13A1 and TM6SF2 genes, and liver injury.","date":"2019","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/30616151","citation_count":5,"is_preprint":false},{"pmid":"36028802","id":"PMC_36028802","title":"PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study.","date":"2022","source":"BMC gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/36028802","citation_count":5,"is_preprint":false},{"pmid":"36685261","id":"PMC_36685261","title":"The TM6SF2 variant as a risk factor for hepatocellular carcinoma development in chronic liver disease patients.","date":"2022","source":"Clinical and experimental hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/36685261","citation_count":5,"is_preprint":false},{"pmid":"40833996","id":"PMC_40833996","title":"Human-induced pluripotent stem cell-based hepatic modeling of lipid metabolism-associated TM6SF2-E167K variant.","date":"2024","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/40833996","citation_count":4,"is_preprint":false},{"pmid":"37400794","id":"PMC_37400794","title":"Metabolic disorders induced by PNPLA3 and TM6SF2 gene variants affect chronic kidney disease in patients infected with non-genotype 3 hepatitis C virus.","date":"2023","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/37400794","citation_count":4,"is_preprint":false},{"pmid":"35143946","id":"PMC_35143946","title":"Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.","date":"2022","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/35143946","citation_count":4,"is_preprint":false},{"pmid":"30572387","id":"PMC_30572387","title":"[Effects of PNPLA3, TM6SF2 gene polymorphisms and its interactions with smoking and alcohol drinking on hepatitis B virus-associated hepatocellular carcinoma].","date":"2018","source":"Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi","url":"https://pubmed.ncbi.nlm.nih.gov/30572387","citation_count":4,"is_preprint":false},{"pmid":"37271250","id":"PMC_37271250","title":"TM6SF2 reduces lipid accumulation in vascular smooth muscle cells by inhibiting LOX-1 and CD36 expression.","date":"2023","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/37271250","citation_count":3,"is_preprint":false},{"pmid":"37495452","id":"PMC_37495452","title":"Effects of TM6SF2 rs58542926 polymorphism on hepatocellular lipids and insulin resistance in early type 2 diabetes.","date":"2023","source":"Nutrition, metabolism, and cardiovascular diseases : NMCD","url":"https://pubmed.ncbi.nlm.nih.gov/37495452","citation_count":3,"is_preprint":false},{"pmid":"34794021","id":"PMC_34794021","title":"Relationships among N,N-dimethylformamide exposure, CYP2E1 and TM6SF2 genes, and non-alcoholic fatty liver disease.","date":"2021","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/34794021","citation_count":3,"is_preprint":false},{"pmid":"37425717","id":"PMC_37425717","title":"TM6SF2 Determines Both the Degree of Lipidation and the Number of VLDL Particles Secreted by the Liver.","date":"2023","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37425717","citation_count":3,"is_preprint":false},{"pmid":"39215018","id":"PMC_39215018","title":"G-quadruplex forming regions in GCK and TM6SF2 are targets for differential DNA methylation in metabolic disease and hepatocellular carcinoma patients.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39215018","citation_count":3,"is_preprint":false},{"pmid":"33685085","id":"PMC_33685085","title":"[Correlation between PNPLA3 rs738409 and TM6SF2 rs58542926 gene polymorphism and primary liver cancer in the Han Population of China's Northeast region].","date":"2021","source":"Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/33685085","citation_count":3,"is_preprint":false},{"pmid":"36904112","id":"PMC_36904112","title":"TM6SF2-rs58542926 Genetic Variant Modifies the Protective Effect of a \"Prudent\" Dietary Pattern on Serum Triglyceride Levels.","date":"2023","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/36904112","citation_count":3,"is_preprint":false},{"pmid":"41492318","id":"PMC_41492318","title":"PNPLA3 and TM6SF2 exacerbate the impact of alcohol and metabolic dysfunction on liver fibrosis.","date":"2025","source":"JHEP reports : innovation in hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/41492318","citation_count":2,"is_preprint":false},{"pmid":"39687601","id":"PMC_39687601","title":"Deep metabolic phenotyping of humans with protein-altering variants in TM6SF2 using a genome-first approach.","date":"2024","source":"JHEP reports : innovation in hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/39687601","citation_count":2,"is_preprint":false},{"pmid":"40806538","id":"PMC_40806538","title":"Contribution of PNPLA3, GCKR, MBOAT7, NCAN, and TM6SF2 Genetic Variants to Hepatocellular Carcinoma Development in Mexican Patients.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40806538","citation_count":1,"is_preprint":false},{"pmid":"38187603","id":"PMC_38187603","title":"Human Induced Pluripotent Stem Cell based Hepatic-Modeling of Lipid metabolism associated TM6SF2 E167K variant.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38187603","citation_count":1,"is_preprint":false},{"pmid":"38408366","id":"PMC_38408366","title":"Inhibition of Cellular Factor TM6SF2 Suppresses Secretion Pathways of Hepatitis B, Hepatitis C, and Hepatitis D Viruses.","date":"2024","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/38408366","citation_count":1,"is_preprint":false},{"pmid":"40065199","id":"PMC_40065199","title":"Association between single nucleotide polymorphisms in PNPLA3, TM6SF2 and MBOAT7 genes and markers of cancer aggressiveness in a Sri Lankan NASH-related HCC cohort.","date":"2025","source":"BMC gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/40065199","citation_count":1,"is_preprint":false},{"pmid":"38163971","id":"PMC_38163971","title":"GDF-10 Induces an Inhibitory Effect on Epithelial-Mesenchymal Transition of Laryngeal Cancer via LPR4.","date":"2023","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/38163971","citation_count":0,"is_preprint":false},{"pmid":"40474882","id":"PMC_40474882","title":"Intestinal Depletion of TM6SF2 Exacerbates High-fat Diet-induced Metabolic Dysfunction-associated Steatotic Liver Disease through the Gut-liver Axis.","date":"2025","source":"Journal of clinical and translational hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/40474882","citation_count":0,"is_preprint":false},{"pmid":"41244049","id":"PMC_41244049","title":"PNPLA3-Ile148Met and TM6SF2-Glu167Lys increase susceptibility to metabolic dysfunction-associated steatotic liver disease in children.","date":"2025","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/41244049","citation_count":0,"is_preprint":false},{"pmid":"40504324","id":"PMC_40504324","title":"Impact of differential detection of TM6SF2 rs58542926 mutation in circulating tumor DNA versus peripheral blood cells on hepatocellular carcinoma patients.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40504324","citation_count":0,"is_preprint":false},{"pmid":"42023869","id":"PMC_42023869","title":"Analysis of PNPLA3, TM6SF2 and GCKR gene polymorphisms in patients with metabolic dysfunction-associated steatohepatitis treated with probiotics ‒ An exploratory study.","date":"2026","source":"Nutricion hospitalaria","url":"https://pubmed.ncbi.nlm.nih.gov/42023869","citation_count":0,"is_preprint":false},{"pmid":"41384813","id":"PMC_41384813","title":"Genetic risk of alcohol-related liver cirrhosis: Associations of PNPLA3, TM6SF2, and a two-variant polygenic risk score.","date":"2025","source":"Biomolecules & biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/41384813","citation_count":0,"is_preprint":false},{"pmid":"37589914","id":"PMC_37589914","title":"A study of genetic variants, genetic risk score and DNA methylation of PNPLA3 and TM6SF2 in alcohol liver cirrhosis.","date":"2023","source":"Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/37589914","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.18.25338158","title":"Modeling Familial MASH by iPSC-Hepatocytes","date":"2025-11-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.18.25338158","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.14.25320567","title":"Discovering Novel Genome Mutations Associated with Liver and Pancreas Disorders: Insights from a Radiogenomics Study","date":"2025-01-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.14.25320567","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.05.24316758","title":"Potential causal links between genetic variants in<i>SAMM50</i>,<i>SUGP1</i>,<i>MAU2</i>, and<i>GATAD2A</i>and liver fat in individuals with normal weight","date":"2024-11-05","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.05.24316758","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.05.06.592717","title":"Circulating mitochondrial bioenergetics as fingerprint of the hepatic one: how to monitor genetic MASLD","date":"2024-05-09","source":"bioRxiv","url":"https://doi.org/10.1101/2024.05.06.592717","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.06.03.597155","title":"Artificial intelligence as a ploy to delve into the intricate relationship between genetics and mitochondria in MASLD patients","date":"2024-06-04","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.03.597155","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55386,"output_tokens":5704,"usd":0.125859},"stage2":{"model":"claude-opus-4-6","input_tokens":9270,"output_tokens":4177,"usd":0.226162},"total_usd":0.352021,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"TM6SF2 is required for normal VLDL secretion; AAV-mediated shRNA knockdown of Tm6sf2 in mice increased liver triglyceride content ~3-fold and decreased VLDL secretion by ~50%. The E167K variant produces ~50% less protein than wild-type when expressed in cultured hepatocytes, indicating the variant causes loss of function.\",\n      \"method\": \"AAV-shRNA knockdown in mice (in vivo), recombinant protein expression in cultured hepatocytes\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean in vivo KO with defined metabolic phenotype, replicated across multiple independent populations and validated in cell culture\",\n      \"pmids\": [\"24531328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TM6SF2 localizes to the endoplasmic reticulum and ER-Golgi intermediate compartment (ERGIC) of human liver cells. siRNA inhibition reduces secretion of triglyceride-rich lipoproteins (TRLs) and increases cellular triglyceride/lipid droplet content, while overexpression reduces hepatocyte steatosis.\",\n      \"method\": \"Confocal microscopy for subcellular localization; siRNA knockdown and overexpression in Huh7 and HepG2 cells with lipoprotein secretion assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment with functional consequence, complementary KD and OE with defined phenotypic readouts\",\n      \"pmids\": [\"24927523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Transient TM6SF2 overexpression or Tm6sf2 knockdown in mice alters serum lipid profiles consistent with human association data, confirming TM6SF2 as the functional gene at the 19p13 locus influencing total cholesterol.\",\n      \"method\": \"In vivo mouse overexpression and knockdown experiments with serum lipid profiling\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gain- and loss-of-function experiments with quantitative lipid phenotyping\",\n      \"pmids\": [\"24633158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Genetic inactivation of Tm6sf2 in mice causes hepatic steatosis, hypocholesterolemia, and transaminitis. TM6SF2 protein localizes to the ER and Golgi complex. VLDL-TG secretion is reduced ~3-fold without reduction in apoB secretion, indicating TM6SF2 is required to mobilize neutral lipids for VLDL lipidation but not for apoB-containing lipoprotein particle secretion per se. Excess lipids accumulate in lipid droplets.\",\n      \"method\": \"Germline Tm6sf2 knockout mouse; immunocytochemistry; cell fractionation; VLDL-TG secretion rate measurement; apoB secretion assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — germline KO with multiple orthogonal mechanistic readouts including fractionation, secretion rates, and lipid quantification\",\n      \"pmids\": [\"27013658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hepatic Tm6sf2 overexpression in mice reduces plasma lipid levels and hepatic TG secretion and increases hepatosteatosis, recapitulating the KO phenotype. In cultured human hepatocytes, Tm6sf2 overexpression reduces apolipoprotein B secretion and causes APOB accumulation within the ER, suggesting impaired ER-to-Golgi trafficking of pre-VLDL particles. Both E167K and L156P coding variants affect TM6SF2 protein stability (altered protein turnover).\",\n      \"method\": \"AAV-mediated hepatic overexpression in mice; APOB trafficking assay in cultured hepatocytes; protein turnover analysis of coding variants\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo overexpression with lipid phenotyping plus mechanistic cell culture experiments with defined trafficking readout\",\n      \"pmids\": [\"28449094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TM6SF2 forms a complex with ERLIN1, ERLIN2, and APOB (identified by tandem affinity purification/mass spectrometry). ERLINs and TM6SF2 mutually stabilize each other. TM6SF2 binds and stabilizes APOB via two luminal loops. ERLINs stabilize APOB indirectly through TM6SF2. The E167K mutation reduces TM6SF2 protein expression and thereby destabilizes APOB. Knockout of Tm6sf2 or Erlins in mice decreases hepatic APOB protein, causing hepatic lipid accumulation and lower serum lipids.\",\n      \"method\": \"Tandem affinity purification + mass spectrometry; Co-IP; mutagenesis of TM6SF2 luminal loops; Tm6sf2 and Erlin knockdown/KO in mice\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — AP-MS identification of interacting proteins followed by reciprocal Co-IP, domain mutagenesis, and in vivo validation\",\n      \"pmids\": [\"32776921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Liver-specific Tm6sf2 knockout (Tm6sf2 LKO) mice develop spontaneous hepatic steatosis with VLDL-TG secretion reduced and small, underlipidated VLDL particles produced with unchanged or increased apoB. Feeding fibrogenic diets exacerbates steatosis and fibrosis, and promotes HCC. AAV8-mediated rescue with either wild-type or E167K-mutant Tm6sf2 reduces hepatic steatosis and restores VLDL secretion, and attenuates tumor burden.\",\n      \"method\": \"Liver-specific conditional KO mice; targeted lipidomics; VLDL-TG secretion assay; AAV8 rescue; HCC models (NASH/STAM and DEN injection)\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two independent LKO lines, rescue experiment, multiple dietary/carcinogen HCC models with quantitative endpoints\",\n      \"pmids\": [\"33638902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TM6SF2 is present predominantly in the smooth ER and ERGIC (not Golgi) of hepatocytes and enterocytes, determined by cell fractionation. TM6SF2 acts in the smooth ER to promote bulk lipidation of apoB-containing lipoproteins. By immunoprecipitation, both apolipoprotein B-48 and acyl-CoA synthetase long chain family member 5 (ACSL5) physically interact with TM6SF2.\",\n      \"method\": \"Cell fractionation; immunoprecipitation; Tm6sf2-/- rat model; perfused liver VLDL lipid content assay; mass spectrometry identification of interacting proteins\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — subcellular fractionation with functional validation, reciprocal Co-IP identifying specific interacting proteins, independent rat KO model\",\n      \"pmids\": [\"34923175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TM6SF2 knockdown in HuH7 hepatoma cells alters membrane lipid composition: accumulation of TAGs, cholesterol esters, PC, and PE, with selective depletion of polyunsaturated lipid species (especially arachidonic acid) and increase in saturated/monounsaturated species. Mitochondrial capacity for palmitate oxidation is significantly reduced. Secreted lipoprotein-like particles are smaller in KD cells.\",\n      \"method\": \"Stable siRNA knockdown in HuH7 cells; lipidomic analysis; mitochondrial fatty acid oxidation assay; lipoprotein particle sizing\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab with multiple orthogonal lipid and functional assays in stable KD cells\",\n      \"pmids\": [\"28434889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TM6SF2 E167K carrier hepatocytes show impaired incorporation of polyunsaturated fatty acids (PUFAs) into triglycerides and phosphatidylcholines (PCs). Liver biopsies from E167K carriers have higher TG and CE but lower PC levels, with PUFA deficiency in liver and serum TGs and liver PCs. TM6SF2 knockdown in HuH-7 cells recapitulates reduced PUFA incorporation into TGs and PCs.\",\n      \"method\": \"Liver biopsies with lipidomic analysis; TM6SF2 knockdown in HuH-7 cells with fatty acid incorporation assay; gene expression analysis\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human liver biopsy lipidomics combined with mechanistic cell culture validation; two orthogonal approaches\",\n      \"pmids\": [\"28235613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TM6SF2 promotes lipidation and secretion of hepatitis C virus lipoviroparticles (LVPs). TM6SF2 knockdown in hepatocytes reduces HCV RNA and infectious LVP secretion without affecting HCV replication, translation, or assembly. TM6SF2 overexpression increases LVP secretion into culture supernatant in lower-density fractions. HCV infection upregulates TM6SF2 expression via SREBF2.\",\n      \"method\": \"TM6SF2 knockdown and overexpression in hepatic cells; iodixanol gradient assay for LVP density; HCV infection assay; measurement of viral RNA and infectious titers; humanized mouse and patient biopsy analysis\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal KD/OE with specific functional readouts, validated in humanized mouse and human biopsies\",\n      \"pmids\": [\"30144428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TM6SF2 CRISPR/Cas9 silencing in HepG2 cells alters lipid composition, induces accumulation of microvesicular lipid droplets, disrupts ER and mitochondrial ultrastructure, increases ER/oxidative stress, and increases mitochondrial number (reflecting imbalanced mitochondrial dynamics). Double knockout of MBOAT7 and TM6SF2 impairs mitochondrial activity with a shift toward anaerobic glycolysis and increases cell proliferation rate. Re-overexpression of TM6SF2 reverses these metabolic and tumorigenic features.\",\n      \"method\": \"CRISPR/Cas9 knockout in HepG2 cells; electron microscopy of ER/mitochondria ultrastructure; lipidomics; metabolic flux analysis; rescue by re-expression\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO with multiple orthogonal mechanistic readouts and rescue experiment\",\n      \"pmids\": [\"34823063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TM6SF2 interacts with inositol-requiring enzyme 1α (IRE1α), a primary ER stress sensor. Male E167K knock-in mice exhibit impaired glucose tolerance and impaired IRE1α signaling in the liver, while female KI mice are unaffected, linking TM6SF2 to ER stress regulation in a sex-specific manner.\",\n      \"method\": \"E167K knock-in mouse model; glucose tolerance tests; Co-IP of TM6SF2 with IRE1α; hepatic IRE1α signaling assays\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KI mouse model with defined phenotype plus Co-IP identifying IRE1α interaction; single lab\",\n      \"pmids\": [\"34746691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Myeloid-specific Tm6sf2 knockout (on ApoE-/- background) inhibits atherosclerosis and reduces foam cell formation without changing plasma lipid profiles. TM6SF2 silencing in macrophages reduces inflammatory responses, ER stress, cholesterol uptake, and foam cell formation; overexpression has opposite effects. TM6SF2 is upregulated by oxidized LDL in macrophages.\",\n      \"method\": \"Myeloid-specific Tm6sf2 KO mice (LysM-Cre); Western diet atherosclerosis model; RNA-seq of BMDMs; THP-1 macrophage siRNA/OE experiments; cholesterol uptake and foam cell assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific in vivo KO with defined atherosclerosis phenotype plus mechanistic cell culture validation\",\n      \"pmids\": [\"36139452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TM6SF2 reduces lipid accumulation in vascular smooth muscle cells (VSMCs) by downregulating LOX-1 (lectin-like oxLDL receptor 1) and CD36 (scavenger receptor) expression in response to oxLDL stimulation.\",\n      \"method\": \"siRNA knockdown and overexpression of TM6SF2 in human aortic VSMCs; lipid accumulation assay; LOX-1 and CD36 expression analysis\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, single cell type, no in vivo validation\",\n      \"pmids\": [\"37271250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The TM6SF2 E167K variant increases the interaction between TM6SF2 and PNPLA3, and impairs PNPLA3-mediated transfer of polyunsaturated fatty acids (PUFAs) from triglycerides to phosphatidylcholines (PCs). E167K KI mice on HFD show decreased polyunsaturated PC and increased polyunsaturated TG. Dietary supplementation with PC containing C18:3 attenuates E167K-induced hepatic steatosis in HFD mice.\",\n      \"method\": \"Tm6sf2 E167K knock-in mice; hepatic lipidomics; thin-layer chromatography of newly synthesized TG/PC; Co-IP of TM6SF2 with PNPLA3; dietary rescue experiment\",\n      \"journal\": \"Clinical and molecular hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KI mouse model plus Co-IP plus lipidomics plus dietary rescue; multiple orthogonal methods\",\n      \"pmids\": [\"39054606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TM6SF2 directly binds IKKβ and inhibits NF-κB signaling, thereby reducing IL-6 secretion from hepatocytes. This mechanism activates cytotoxic CD8+ T cells and suppresses MASLD-related HCC. Hepatocyte-specific Tm6sf2 KO increases IL-6 and reduces IFN-γ+CD8+ T cells in tumors; IL-6 neutralization abolishes the tumor-promoting effect of Tm6sf2 KO.\",\n      \"method\": \"Hepatocyte-specific Tm6sf2 KO mice; HFHC diet and DEN-induced HCC models; orthotopic HCC model; Co-IP of TM6SF2 with IKKβ; IL-6 neutralization; CD8+ T cell depletion; adenovirus-mediated rescue\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific KO with mechanistic Co-IP, rescue, and depletion experiments across multiple HCC models\",\n      \"pmids\": [\"39667906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Intestinal epithelial cell-specific Tm6sf2 knockout (Tm6sf2ΔIEC) mice develop MASH accompanied by impaired intestinal barrier and microbial dysbiosis. Stool transplant from Tm6sf2ΔIEC mice induces steatohepatitis in germ-free recipients. Mechanistically, Tm6sf2-deficient intestinal cells interact with fatty acid-binding protein 5 (FABP5) to secrete more free fatty acids, causing gut barrier dysfunction and enrichment of pathobionts. This elevates lysophosphatidic acid (LPA) that translocates to the liver to promote lipid accumulation and inflammation.\",\n      \"method\": \"Intestinal-specific Tm6sf2 KO mice; germ-free fecal transplant; co-housing rescue; Co-IP with FABP5; LPA receptor pharmacological inhibition; gut microbiome analysis\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models (IEC-KO, GF transplant, co-housing), mechanistic Co-IP, and pharmacological intervention with defined pathway\",\n      \"pmids\": [\"39779889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In iPSC-derived hepatocytes carrying the TM6SF2 E167K mutation, TM6SF2 protein expression is decreased, intracellular lipid droplets and total cholesterol are increased, and VLDL secretion is reduced. Signs of ER stress and mitochondrial dysfunction are observed. Facilitating protein folding within the ER of E167K hepatocytes improves VLDL secretion and reduces ER stress markers.\",\n      \"method\": \"CRISPR gene editing of iPSCs; hepatocyte-directed differentiation; lipidomics; transcriptomics; ER chaperone treatment rescue experiment\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — human iPSC-derived hepatocyte model with mechanistic rescue experiment; single lab\",\n      \"pmids\": [\"40833996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Inhibition (knockdown) of TM6SF2 in viral hepatitis cell culture models suppresses secretion of infectious HCV virions, HDV virions, and HBV subviral particles, indicating TM6SF2 functions in the ER-Golgi secretion pathway exploited by multiple hepatitis viruses.\",\n      \"method\": \"TM6SF2 knockdown in HBV, HCV, HDV cell culture infection models; measurement of secreted infectious particles and subviral particles; correlation with human cohort polymorphism data\",\n      \"journal\": \"The Journal of infectious diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — consistent KD phenotype across three different viral infection models; human cohort validation\",\n      \"pmids\": [\"38408366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Computational sequence analysis identified a conserved EXPERA domain shared among TM6SF2, MAC30/TMEM97, and EBP (D8/D7 sterol isomerase) protein families, predicting that TM6SF2 may possess catalytic activity as a sterol isomerase.\",\n      \"method\": \"Computational protein sequence analysis and evolutionary conservation analysis\",\n      \"journal\": \"Frontiers in genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational prediction only, no experimental validation\",\n      \"pmids\": [\"25566323\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TM6SF2 is an ER-resident polytopic membrane protein (also present in the ERGIC) that promotes bulk lipidation of nascent apoB-containing VLDL particles in the smooth ER by physically interacting with APOB, ACSL5, ERLIN1/2, and PNPLA3; loss of function (including the E167K variant, which destabilizes the protein) impairs PUFA incorporation into phosphatidylcholines and reduces VLDL-TG secretion, causing hepatic lipid droplet accumulation, while in macrophages TM6SF2 promotes cholesterol uptake and inflammation, and in intestinal cells it regulates free fatty acid secretion via FABP5 to modulate the gut-liver LPA axis; additionally, hepatic TM6SF2 suppresses NF-κB/IL-6 signaling by binding IKKβ to maintain anti-tumor CD8+ T cell immunity, and facilitates ER-Golgi secretion of hepatitis B, C, and D viruses.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TM6SF2 is an ER-resident polytopic membrane protein that controls the lipidation and secretion of apolipoprotein B-containing lipoproteins, with broad roles in hepatic, intestinal, and macrophage lipid metabolism, innate immune signaling, and hepatitis virus egress. In the smooth ER and ERGIC, TM6SF2 physically interacts with APOB, ACSL5, ERLIN1/2, and PNPLA3 to promote bulk neutral-lipid loading of nascent VLDL particles and the channeling of polyunsaturated fatty acids from triglycerides into phosphatidylcholines; loss of function — including the common E167K destabilizing variant — reduces VLDL-TG secretion and causes hepatic steatosis, ER stress, and progression to fibrosis and hepatocellular carcinoma [PMID:24531328, PMID:27013658, PMID:32776921, PMID:39054606]. Beyond lipoprotein metabolism, TM6SF2 suppresses NF-κB/IL-6 signaling by binding IKKβ to sustain anti-tumor CD8⁺ T cell immunity in the liver, promotes cholesterol uptake and inflammatory responses in macrophages, and in intestinal epithelial cells interacts with FABP5 to regulate free fatty acid secretion and gut-barrier integrity via the lysophosphatidic acid–liver axis [PMID:39667906, PMID:36139452, PMID:39779889]. TM6SF2 also facilitates ER-to-Golgi secretion of hepatitis B, C, and D virions, linking its lipid-trafficking function to the life cycles of multiple hepatotropic viruses [PMID:30144428, PMID:38408366].\",\n  \"teleology\": [\n    {\n      \"year\": 2014,\n      \"claim\": \"Establishing TM6SF2 as the causal gene at the 19p13 NAFLD/dyslipidemia locus resolved a key gene-assignment question: in vivo knockdown caused hepatic steatosis and reduced VLDL secretion, while E167K reduced protein levels, defining loss-of-function as the disease mechanism.\",\n      \"evidence\": \"AAV-shRNA knockdown in mice; recombinant expression of WT vs E167K in hepatocytes; independent overexpression/knockdown mouse cohorts with serum lipid profiling\",\n      \"pmids\": [\"24531328\", \"24633158\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural data for TM6SF2 or the E167K mutation\", \"Mechanism by which TM6SF2 promotes lipidation unknown\", \"Tissue-specific contributions not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Subcellular localization to the ER and ERGIC placed TM6SF2 at the site of VLDL assembly and linked its function to the early secretory pathway rather than post-Golgi trafficking.\",\n      \"evidence\": \"Confocal microscopy and cell fractionation in Huh7/HepG2 cells; siRNA/overexpression with lipoprotein secretion readouts\",\n      \"pmids\": [\"24927523\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TM6SF2 cycles between ER and ERGIC or is static was unresolved\", \"Identity of direct protein partners unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Germline Tm6sf2 KO demonstrated that TM6SF2 is specifically required for neutral-lipid loading onto VLDL (reduced VLDL-TG without reduced apoB secretion), separating bulk lipidation from particle assembly.\",\n      \"evidence\": \"Germline Tm6sf2 knockout mouse with VLDL-TG secretion rates and apoB secretion measurement\",\n      \"pmids\": [\"27013658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TM6SF2 mobilizes neutral lipids to VLDL remained unknown\", \"Lipid species specificity not yet characterized\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Lipidomic analyses of TM6SF2-deficient cells and E167K carrier livers revealed selective impairment of polyunsaturated fatty acid incorporation into triglycerides and phosphatidylcholines, identifying a lipid-species-specific function beyond bulk TG mobilization.\",\n      \"evidence\": \"Lipidomics of human liver biopsies from E167K carriers; fatty acid incorporation assays in TM6SF2-knockdown HuH-7 cells; membrane lipid profiling of stable KD cells\",\n      \"pmids\": [\"28235613\", \"28434889\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymatic versus scaffolding role in PUFA channeling unclear\", \"No direct enzymatic assay performed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Overexpression studies showed that excess TM6SF2 impairs ER-to-Golgi trafficking of APOB, and that both E167K and L156P reduce protein stability, indicating that TM6SF2 dosage — not just presence — is critical for VLDL export.\",\n      \"evidence\": \"AAV-mediated hepatic overexpression in mice; APOB trafficking in cultured hepatocytes; protein turnover of coding variants\",\n      \"pmids\": [\"28449094\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether overexpression artifact or true stoichiometric requirement was debated\", \"Degradation pathway of destabilized TM6SF2 not identified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Discovery that TM6SF2 promotes HCV lipoviroparticle secretion without affecting viral replication or assembly extended TM6SF2 function from endogenous lipoprotein export to virus egress, exploiting the same ER lipidation machinery.\",\n      \"evidence\": \"TM6SF2 knockdown/overexpression in HCV-infected hepatocytes; iodixanol gradient density profiling of secreted virions; humanized mouse validation\",\n      \"pmids\": [\"30144428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TM6SF2 directly contacts viral proteins or acts only via lipoprotein lipidation was unclear\", \"Applicability to other hepatitis viruses not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of a TM6SF2–ERLIN1/2–APOB complex revealed the molecular partners through which TM6SF2 stabilizes APOB in the ER: two luminal loops of TM6SF2 bind APOB directly, while ERLINs stabilize the complex, explaining how E167K reduces APOB protein.\",\n      \"evidence\": \"Tandem affinity purification–mass spectrometry; reciprocal Co-IP; luminal loop mutagenesis; Tm6sf2 and Erlin KO mice\",\n      \"pmids\": [\"32776921\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the complex undefined\", \"Whether ERLIN-TM6SF2 interaction is constitutive or regulated unknown\", \"No structural model of the complex\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Liver-specific Tm6sf2 KO confirmed cell-autonomous hepatocyte function and showed that TM6SF2 loss promotes diet-dependent fibrosis and HCC, with rescue by AAV-delivered WT or E167K TM6SF2, establishing TM6SF2 as a liver tumor suppressor.\",\n      \"evidence\": \"Liver-specific conditional KO mice; NASH/STAM and DEN HCC models; AAV8 rescue with WT and E167K\",\n      \"pmids\": [\"33638902\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"HCC mechanism (steatosis-driven vs direct signaling) not dissected\", \"Whether E167K rescue reflects residual function or dosage restoration unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Refined fractionation placed TM6SF2 in the smooth ER and ERGIC (not Golgi), and identification of ACSL5 as a physical partner linked TM6SF2 to fatty acyl-CoA metabolism at the site of VLDL lipidation.\",\n      \"evidence\": \"Cell fractionation of hepatocytes and enterocytes; immunoprecipitation identifying apoB-48 and ACSL5 as partners; Tm6sf2 KO rat model\",\n      \"pmids\": [\"34923175\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of ACSL5 interaction not tested by ACSL5 perturbation\", \"Whether TM6SF2 channels acyl-CoAs directly to VLDL or lipid droplets unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"CRISPR knockout revealed that TM6SF2 loss disrupts ER and mitochondrial ultrastructure, increases ER/oxidative stress, shifts metabolism toward glycolysis, and promotes cell proliferation — linking TM6SF2 to organelle homeostasis and tumorigenesis beyond lipid secretion.\",\n      \"evidence\": \"CRISPR/Cas9 KO in HepG2; electron microscopy; metabolic flux analysis; rescue by re-expression; MBOAT7/TM6SF2 double KO\",\n      \"pmids\": [\"34823063\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether mitochondrial phenotype is secondary to ER lipid overload or a direct TM6SF2 function unresolved\", \"In vivo replication of metabolic reprogramming not performed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Myeloid-specific Tm6sf2 KO demonstrated a non-hepatocyte role: TM6SF2 promotes macrophage cholesterol uptake and inflammation, and its deletion reduces atherosclerosis, revealing cell-type-dependent opposing effects on disease.\",\n      \"evidence\": \"LysM-Cre myeloid-specific Tm6sf2 KO on ApoE⁻/⁻ background; Western diet atherosclerosis model; THP-1 siRNA/OE with cholesterol uptake assays\",\n      \"pmids\": [\"36139452\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of cholesterol uptake promotion in macrophages not identified\", \"Whether hepatic and macrophage functions share the same molecular partners unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Co-IP showed that E167K increases TM6SF2 interaction with PNPLA3, impairing PNPLA3-mediated PUFA transfer from TG to PC; dietary PC supplementation rescued steatosis, establishing the TM6SF2–PNPLA3 axis as a targetable lipid-remodeling pathway.\",\n      \"evidence\": \"E167K knock-in mice on HFD; Co-IP of TM6SF2 with PNPLA3; TLC of newly synthesized TG/PC; dietary rescue with C18:3-containing PC\",\n      \"pmids\": [\"39054606\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TM6SF2 directly modulates PNPLA3 catalytic activity or only proximity unknown\", \"Structural basis of increased E167K–PNPLA3 interaction not determined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of IKKβ as a TM6SF2 binding partner and demonstration that TM6SF2 suppresses NF-κB/IL-6 signaling to maintain CD8⁺ T cell anti-tumor immunity revealed a non-lipid, immunomodulatory mechanism through which TM6SF2 loss promotes HCC.\",\n      \"evidence\": \"Hepatocyte-specific Tm6sf2 KO; HFHC and DEN HCC models; Co-IP with IKKβ; IL-6 neutralization; CD8⁺ T cell depletion; adenovirus rescue\",\n      \"pmids\": [\"39667906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IKKβ binding is direct or mediated by a complex member unclear\", \"Relationship between lipid and NF-κB functions not disentangled\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extending the viral egress function, TM6SF2 knockdown suppressed secretion of HBV subviral particles and HDV virions alongside HCV, establishing TM6SF2 as a shared host factor for multiple hepatitis viruses.\",\n      \"evidence\": \"TM6SF2 knockdown in HBV, HCV, and HDV cell culture infection models; secreted particle quantification\",\n      \"pmids\": [\"38408366\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vivo viral model tested\", \"Whether TM6SF2 acts via a common lipidation step for all viruses or through distinct mechanisms unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Intestinal epithelial-specific Tm6sf2 KO and germ-free fecal transplant demonstrated that TM6SF2 in enterocytes maintains gut-barrier integrity; loss increases FABP5-dependent free fatty acid secretion, microbial dysbiosis, and LPA-mediated liver injury, establishing a gut-liver axis for TM6SF2-driven MASH.\",\n      \"evidence\": \"IEC-specific Tm6sf2 KO mice; germ-free fecal microbiota transplant; Co-IP with FABP5; LPA receptor inhibition; microbiome analysis\",\n      \"pmids\": [\"39779889\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether intestinal TM6SF2–FABP5 interaction governs the same PUFA-channeling seen in hepatocytes unknown\", \"Contribution of intestinal vs hepatic TM6SF2 loss to human MASH not quantified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"No high-resolution structure of TM6SF2 exists, the catalytic versus scaffolding nature of TM6SF2 in lipid remodeling is unresolved, and how its lipid-trafficking and NF-κB-suppressive functions are coordinated remains an open question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure available\", \"Whether TM6SF2 possesses enzymatic (e.g. sterol isomerase) activity remains untested experimentally\", \"Integration of hepatocyte, macrophage, and enterocyte functions into a unified model lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [8, 9, 15]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 16]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [5, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1, 3, 7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 3, 6, 8, 9, 15]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [4, 5, 7, 10]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 16]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13, 16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [6, 10, 11, 19]}\n    ],\n    \"complexes\": [\n      \"TM6SF2–ERLIN1/2–APOB complex\"\n    ],\n    \"partners\": [\n      \"APOB\",\n      \"ERLIN1\",\n      \"ERLIN2\",\n      \"ACSL5\",\n      \"PNPLA3\",\n      \"FABP5\",\n      \"IKBKB\",\n      \"ERN1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}